Medicare to Cover Multi-Cancer Blood Tests Starting in 2028: New Bill Targets Early Detection for Seniors

Imagine catching cancer with a single blood draw before you even feel a symptom. That is the goal of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. Starting January 1, 2028, Medicare will officially add 'multi-cancer early detection' (MCED) tests to its list of covered benefits. These aren't your standard screenings; they use genomic sequencing to scan for multiple types of cancer at once by looking at cell-free nucleic acids in your blood. To get the green light for coverage, a test has to be FDA-approved and deemed 'reasonable and necessary' by the Secretary of Health and Human Services. For a senior who might otherwise face a dozen different invasive tests, this could mean a much simpler path to peace of mind.

The Age Bracket and Timing

There is some fine print on who gets this and when. The bill sets a rolling age limit to manage the rollout: in 2028, you are covered if you are up to age 68. Every year after that, the limit bumps up by one year—so in 2029, it’s age 69, and so on. You can only get the test once every 12 months. However, there is a shortcut to broader access: if the U.S. Preventive Services Task Force gives a specific test a high grade (an A or B), those age and frequency restrictions get tossed out. This means if the tech proves to be a home run for public health, the government is prepared to open the floodgates sooner.

Paying the Tab

Between 2028 and 2031, Medicare will pay for these new blood tests at the same rate it currently pays for multi-target stool DNA tests (think Cologuard). After 2031, the payment shifts to a more permanent formula based on market rates. For a retired office manager or a former construction worker on a fixed income, this coverage is the difference between accessing cutting-edge tech and being priced out of early detection. The bill also makes it clear that this isn't a 'one or the other' situation; getting this blood test won't disqualify you from your regular mammogram, colonoscopy, or prostate screening.

The Secretary’s Call

While the bill is a big step forward, it gives the Secretary of Health and Human Services a fair amount of 'vague authority' to decide which tests are 'comparable' to the high-end genomic ones. This means the government has some wiggle room in deciding which lab companies get paid and which don't. For the average person, the challenge will be navigating the transition as this tech evolves. While the bill aims to save lives by catching illness early—potentially lowering long-term treatment costs for everyone—the actual impact will depend on how quickly the FDA and the HHS Secretary move to approve the latest tests hitting the market.